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Reduced Competitiveness of Autoantigen-Engaged
B Cells due to Increased Dependence on BAFF
(Benschop et al., 2001; Goodnow et al., 1988; Lang and
Nemazee, 2000; Mandik-Nayak et al., 1997).
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B cells bind HEL-autoantigen, yet they are still presentUniversity of Colorado Health Sciences Center
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genic mice lacking autoantigen (Mason et al., 1992). B
cell lifespan measurements in the Ig/HEL double trans-
genic mice indicated a 50% turnover time of 1 week,
Summary and showed that as many as 40% of the cells lived
considerably longer than this (Cook et al., 1997; Cyster
Peripheral autoantigen binding B cells are poorly com- and Goodnow, 1995; Fulcher and Basten, 1994). How-
petitive with naive B cells for survival and undergo ever, when small numbers of Ig/HEL-double transgenic
rapid cell death. However, in monoclonal Ig-transgenic B cells were transferred into a mouse with a diverse B
mice lacking competitor B cells, autoantigen binding cell repertoire—mimicking the situation in Hc-only trans-
B cells can survive for extended periods. The basis for genic mice—the autoantigen binding cells underwent
competitive elimination of autoantigen binding B cells cell death within 2 to 3 days (Cyster and Goodnow;
has been unknown. Here we demonstrate that autoan- Cyster et al., 1994). These findings indicated that in the
tigen binding B cells have increased dependence on presence of a diverse repertoire of competitor B cells,
BAFF for survival. In monoclonal Ig-transgenic mice, soluble HEL autoantigen binding B cells are rapidly elim-
each autoantigen binding B cell receives elevated inated. Early studies indicated that autoantigen binding
amounts of BAFF, exhibiting increased levels of NFB B cells were blocked from entering follicles prior to their
p52 and of the prosurvival kinase Pim2. When placed elimination, leading to a model where B cells compete
in a diverse B cell compartment, BAFF receptor en- for a trophic factor present within follicles (Cyster et al.,
gagement and signaling are reduced and the autoanti- 1994). However, recent experiments with CCR7-defi-
gen binding cells are unable to protect themselves cient cells have indicated that autoantigen binding B
from Bim and possibly other death-promoting factors cells undergo competitive elimination even when they
induced by chronic BCR signaling. These findings indi- are not excluded from follicles (Ekland et al., 2004), sug-
cate that under conditions where BAFF levels are ele- gesting competition for a more widely distributed factor.
vated, autoantigen-engaged cells will be rescued from Competitive elimination is independent of T cells or Fas
rapid competitive elimination, predisposing to the de- and can be substantially delayed by Bcl2 overexpres-
velopment of autoimmune disease. sion (Cyster et al., 1994; Mandik-Nayak et al., 2000;
Schmidt and Cyster, 1999), but the nature of the proapo-
ptotic signals transmitted by the chronically engagedIntroduction
BCR has not been defined. Recent studies in T cells
have highlighted a role for the proapoptotic BH3-onlyAutoreactive B cells are negatively selected by mecha-
molecule, Bim, in the death of autoreactive cells (Bouilletnisms of receptor editing and deletion in the bone mar-
et al., 2002; Davey et al., 2002; Hildeman et al., 2002),row (Goodnow, 2001; Nemazee, 2000). However, some
and a role for Bim in B cells is indicated by the markedautoreactive B cells escape these early checkpoints and
increase in B cell numbers and production of autoanti-
emigrate to the periphery. Using immunoglobulin (Ig)
bodies that occurs in Bim-deficient mice (Bouillet et
transgenic models, it has been established that periph-
al., 1999).
eral B cells chronically exposed to weakly crosslinking BAFF (also known as BLyS, TALL-1, THANK, zTNF4,
autoantigens downregulate their surface IgM and par- or TNFS13b), a member of the TNF family of cytokines,
tially uncouple the remaining B cell receptors (BCR) from has emerged as a critical B cell survival factor (Mackay
downstream signaling pathways (Goodnow, 2001). This et al., 2003). BAFF expression has been detected pre-
has been observed with B cells specific for the neo- dominantly in lymphoid tissues and in peripheral blood
self-antigen, soluble hen egg lysozyme (HEL), for B cells mononuclear cells (Moore et al., 1999; Mukhopadhyay
reactive with dsDNA, and for arsonate-specific B cells et al., 1999; Schneider et al., 1999; Shu et al., 1999). In
that are also reactive with an unknown autoantigen vivo studies have demonstrated that increased BAFF
levels lead to increased peripheral B cell numbers (Bat-
ten et al., 2000; Gross et al., 2000; Khare et al., 2000;*Correspondence: cyster@itsa.ucsf.edu
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Mackay et al., 1999; Moore et al., 1999), whereas when than non-autoantigen binding B cells for survival. We
BAFF is neutralized, peripheral B cell numbers decrease provide evidence that homeostatic BAFF production is
(Gross et al., 2000, 2001; Schneider et al., 2001; Thomp- independent of B cell numbers and in Ig/HEL-double
son et al., 2000), indicating a tight relationship between transgenic mice the number of B cells is reduced such
BAFF levels and homeostatic B cell numbers. Further- that each cell is engaged by higher amounts of BAFF.
more, BAFF transgenic mice develop diseases resem- Within a diverse B cell compartment, the competition
bling systemic lupus erythematosus (SLE) and Sjo¨gren’s between B cells for the available BAFF is such that
syndrome (SS) (Batten et al., 2000; Groom et al., 2002; autoantigen binding B cells are unable to bind the high
Gross et al., 2000; Khare et al., 2000; Mackay et al., levels of BAFF that they require for survival and they
1999), and SLE-prone NZB/W F1 mice have increased are rapidly eliminated.
levels of BAFF in their serum (Gross et al., 2000; Kaya-
gaki et al., 2002). BAFF levels are also elevated in hu- Results
mans with autoantibody-mediated diseases (Groom et
al., 2002; Mackay et al., 2002; Mariette et al., 2003). Increased BAFF Dependence of HEL-Autoantigen
Three BAFF binding receptors have been identified, Binding B Cells
BAFF receptor (BAFF-R, also called BR3), B cell matura- To test the dependence of HEL autoantigen binding B
tion antigen (BCMA), and transmembrane activator and cells on BAFF for survival, we used an adoptive transfer
CAML interactor (TACI) (Mackay et al., 2003). Studies approach where mature non- or Ig/HEL-double trans-
examining A/WySnJ mice that harbor a spontaneous genic B cells were transferred to matched recipients
mutation in the BAFF-R gene and in BAFF knockout that were either left untreated or treated with the BAFF
mice have demonstrated that BAFF-R is the key receptor antagonist, BCMA-Ig. Consistent with other findings
involved in promoting B cell survival (Gross et al., 2001; (Gross et al., 2000; Harless et al., 2001; Pelletier et al.,
Lentz et al., 1996, 1998; Miller and Hayes, 1991; Schie- 2003), we found that mature nontransgenic B cells were
mann et al., 2001). By contrast, BCMA-deficient mice dependent on constant BAFF exposure, with their num-
have a normal B cell compartment and TACI-deficient bers in BCMA-Ig-treated mice declining to half of the
mice exhibit exaggerated B cell activity, suggesting a control numbers by 3 days and to 25% of the control
possible role for TACI as a negative regulatory molecule by 7 days (Figure 1A), whereas cotransferred T cells
(von Bulow et al., 2001; Xu and Lam, 2001; Yan et al., were unaffected by BAFF antagonism (Figure 1A). Com-
2001b). Expression analysis indicates that BAFF-R is pared to the nontransgenic B cells, the HEL-autoantigen
upregulated during B cell maturation and is expressed binding B cells underwent a more marked reduction in
at highest levels on peripheral B cells (Avery et al., 2003; cell number such that after 2.5 days, less than 15% of
Gorelik et al., 2004; Smith and Cancro, 2003). By con- the transferred anergic B cells remained in mice treated
trast, TACI and BCMA mRNA are not upregulated during with BCMA-Ig (Figure 1B). This rapid elimination of au-
B cell maturation, and in a recent study these receptors toantigen binding B cells is comparable to the competi-
were not detected on resting human B cells by flow tive elimination seen when Ig/HEL double transgenic B
cytometry (Avery et al., 2003; Smith and Cancro, 2003). cells are transferred into a HEL-expressing mouse with
While both TACI and BCMA can bind a cytokine closely a diverse B cell repertoire (Figure 1B) (Cyster and Good-
related to BAFF, known as APRIL, BAFF-R binds BAFF now, 1995). To test whether HEL-autoantigen binding B
exclusively (Thompson et al., 2001; Yan et al., 2001a) cells are also more sensitive to partial reductions in
and APRIL does not appear to have a role in B cell BAFF levels, Ig/HEL-double transgenic B cells and non-
homeostasis (Varfolomeev et al., 2004). BAFF-R, but not
transgenic B cells were cotransferred into Ig/HEL-dou-
TACI or BCMA, activate NFB-inducing kinase (NIK) and
ble transgenic mice that were then treated with 30 or 100
the alternative NFB pathway, leading to p100 degrada-
g doses of BCMA-Ig or with human IgG as a control.tion and generation of p52 (Claudio et al., 2002; Kayagaki
As a further control, naive Ig-transgenic B cells wereet al., 2002). Consistent with a critical role for this path-
transferred into nontransgenic recipients and these ani-way in B cell survival, mice lacking NIK or p52 show
mals were also treated with BCMA-Ig or human IgG. Atsevere deficiencies in peripheral B cells (Claudio et al.,
the 30 g dose of BCMA-Ig, the HEL-autoantigen bind-2002; Miosge et al., 2002). BAFF-R, as well as TACI
ing B cells were reduced by more than 80% at day 3and BCMA, also activate the classical NF-B pathway
whereas the naive nontransgenic and Ig-transgenic B(Hatada et al., 2003; Mukhopadhyay et al., 1999). The
cells were only marginally reduced in number (Figuremechanism by which BAFF and the alternative pathway
1C). Similar results were seen in lymph nodes and bloodof NFB activation leads to enhanced B cell survival
(not shown). These observations indicate that HEL au-is unclear. Although activation of the BAFF pathway
toantigen binding B cells are more sensitive to BAFFpromotes small increases in Bcl-xL, A1, and possibly
depletion than naive B cells and they die more rapidlyBcl-2 expression (Claudio et al., 2002; Do et al., 2000;
when BAFF is removed.Hatada et al., 2003; Hsu et al., 2002), there is as yet no
consensus on whether these or other molecules are the
Increased BAFF per B Cell in Ig/HEL Doublekey mediators of BAFF’s strong prosurvival effects.
Transgenic MiceIn this study we set out to understand the molecular
The above findings led us to consider the possibilitymechanisms regulating the rapid competitive elimina-
that Ig/HEL double transgenic B cells may be dependenttion of autoantigen binding B cells in a diverse B cell
on higher levels of BAFF for survival compared to naiverepertoire. We demonstrate that HEL-autoantigen bind-
B cells. To test this possibility, we first examined theing B cells have elevated levels of Bim mRNA and protein
and that they are dependent on higher levels of BAFF level of BAFF mRNA expression in various mouse tis-
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BAFF mRNA levels in spleen cell supension and “stro-
mal” fractions revealed strong enrichment for BAFF in
the stromal fraction (Figure 2A). Splenic BAFF mRNA
levels were not substantially affected by deficiency in
LT, LT, or TNF, consistent with the lack of evidence
for B cell deficiencies in these mice (Fu and Chaplin,
1999), but also suggesting that LT- and TNF-dependent
follicular dendritic cells (FDC) are not a major source of
BAFF (Figure 2B). CSF1-deficient op/op spleens also
contained amounts of BAFF message that were within
the normal range, suggesting marginal zone macro-
phages are not a major source of this cytokine (Figure
2B). Importantly, BAFF expression was not reduced in
Rag1/ and MT spleens, indicating that the amount
of BAFF mRNA produced in the spleen in homeostasis
is largely independent of the presence or absence of B
cells (Figure 2B).
As Ig/HEL-double transgenic mice have approxi-
mately 2- to 3-fold fewer B cells than Ig- and nontrans-
genic mice, we considered the possibility that more
BAFF may be available per HEL-autoantigen binding B
cell in an Ig/HEL-double transgenic mouse than in a
nontransgenic mouse. To measure this, we quantitated
BAFF mRNA in lymphoid tissues from Ig/HEL-double
transgenic or nontransgenic mice, and also CD19 mRNA
as a measure of the B cell content of the tissues (Figure
2C). By flow cytometric analysis, CD19 levels on HEL-
autoantigen binding and nontransgenic B cells were
identical (data not shown). As a proportion of total RNA,
levels of BAFF mRNA in the secondary lymphoid organs
of the two types of mice were similar, whereas the
Figure 1. Autoreactive B Cells Have Increased Dependence on amount of CD19 mRNA was lower in the Ig/HEL-double
BAFF for Survival transgenic organs, reflecting the lower B cell numbers
(A) BAFF dependence of mature nontransgenic B cells. Mature (Figure 2C). Therefore, when the ratio of BAFF mRNA
lymph node B and T cells from CD45.1 mice were adoptively trans-
to CD19 mRNA is considered, it is evident that there isferred into congenic CD45.2 recipients. Recipient mice were
more BAFF expressed per autoantigen binding Ig/HEL-treated with 100 g of control huIgG or huBCMA-Ig for 3 or 7 days,
double transgenic B cell than is expressed per nontrans-at which time CD45.1 T and B cells in the spleen were quantitated.
Each point represents an individual animal and bars represent the genic B cell (Figure 2C). Serum ELISA analysis demon-
mean. Data are representative of two similar experiments. strated that the difference in BAFF mRNA per B cell
(B and C) Elevated dependence of autoantigen binding B cells on translated into a large difference in the abundance of
BAFF. In (B), spleen cells from CD45.1 Ig/HEL-double transgenic serum BAFF, with Ig/HEL double transgenic mouse se-
mice were transferred into CD45.2Ig/HEL-double transgenic or
rum containing 90 ng/ml compared to undetectableHEL-transgenic recipients. In (C), spleen cells from CD45.1 Ig/HEL-
levels in the non- or HEL-transgenic mice (Figure 2D).double transgenic mice or CD45.1 Ig-single transgenic mice were
Ig-transgenic mice, which have somewhat fewer B cellscotransferred with CD45.1 nontransgenic spleen cells into the indi-
cated CD45.2 recipients. Recipient mice were treated with 100 g than nontransgenic mice, had slightly higher levels of
(B) or the indicated amounts (C) of control huIgG or huBCMA-Ig at serum BAFF than nontransgenics (Figure 2D), while B
the time of cell transfer. After 2.5 days, transferred (CD45.1) B and cell-deficient MT mice showed significantly higher
T cells were quantitated in the recipient spleens. In (C), Ig-transgenic amounts of BAFF (833  46 ng/ml, n  3).
B cells were distinguished from cotransferred nontransgenic B cells
As a further approach to measure BAFF availabilityby IgDa and HEL/HyHEL9 staining and the nontransgenic B cell data
per B cell, we measured the amounts of BAFF proteinshown are for the cells cotransferred with the Ig/HEL cells. In control
bound to B cells in lymphoid organs by ex vivo flowtreated mice, transferred Ig/HEL-, Ig-, and nontransgenic B cells
survived similarly, as in previous studies (Cyster and Goodnow, cytometric analysis. In preliminary experiments, we ob-
1995), and 3–9 	105 transferred cells were present per spleen. Data served that freshly isolated B cells can be stained with
are shown as mean sd of three mice per group and are representa- antibodies against the soluble portion of BAFF (Figure
tive of three experiments. 3A). This staining was increased if cells were preincu-
bated with further BAFF in vitro and diminished if mice
were pretreated with BCMA-Ig to deplete endogeous
sues by quantitative PCR. High levels of BAFF mRNA BAFF, providing evidence of staining specificity (Figure
were detected in secondary lymphoid tissues and within 3A). Incubation of B cells at 37
C for up to 3 hr in the
blood cells (Figure 2A), consistent with previous reports absence of added BAFF did not alter the amount of
(Moore et al., 1999; Mukhopadhyay et al., 1999; Schnei- BAFF associated with the cells (data not shown), sug-
der et al., 1999; Shu et al., 1999; Tribouley et al., 1999). gesting a long half-life for the BAFF-BAFF-R complex,
High levels were also detected in peritoneal lavage cells consistent with studies indicating a high affinity (Kd0.1
nM) for this interaction and also with evidence that BAFFand within bone marrow (Figure 2A). Comparison of
Immunity
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Figure 2. BAFF Expression Analysis and Elevated Levels of BAFF mRNA per B Cell in Ig/HEL Double Transgenic Mice
(A and B) Quantitative RT-PCR analysis of BAFF mRNA expression in (A) various tissues from wild-type mice and (B) in spleen tissue from
mice of the indicated genotypes. Values were normalized to HPRT mRNA in each sample. PLN, peripheral lymph nodes (a mixture of axillary,
brachial and inguinal); mLN, mesenteric lymph nodes; Perit., peritoneal lavage cells. All mice were on a C57Bl/6 background. The number of
samples per group is shown in each bar and the bar represents mean  sd.
(C) Estimation of BAFF mRNA levels per B cell in Ig/HEL double transgenic and nontransgenic mice. Quantitative RT-PCR was performed to
measure BAFF mRNA (left panel) and CD19 mRNA (center panel) in lymphoid tissues of the indicated mice. The right panel shows the ratio
of BAFF mRNA to CD19 mRNA as a measure of BAFF expression per B cell.
(D) ELISA analysis of serum BAFF levels in the indicated mice.
exists as a homotrimer and possibly a higher order com- (data not shown). Initially we considered the possibility
that the lower BAFF-R level might be due to the effectsplex (Kanakaraj et al., 2001; Kayagaki et al., 2002; Kim
et al., 2003; Pelletier et al., 2003). To compare the amount of chronic BCR signaling. However, when nontransgenic
B cells were transferred to recipient Ig/HEL-doubleof BAFF protein available per B cell in Ig/HEL-double
transgenic mice and mice that have a full compartment transgenic mice for 12 or more hr the level of BAFF-R
was also found to be reduced (Figure 3C, middle panel),of B cells, congenically marked nontransgenic B cells
were transferred to Ig/HEL-double transgenic or HEL- an effect that could not be attributed to autoantigen
binding. Instead this observation suggested that thesingle transgenic recipients. Six hours after transfer,
significantly greater amounts of BAFF were bound to elevated levels of BAFF in Ig/HEL-double transgenic
mice induced downmodulation of the receptor. Down-transferred B cells in Ig/HEL-double transgenic recipi-
ents than in HEL-transgenic recipients (Figure 3B, upper regulation required 12 or more hr of in vivo exposure to
elevated BAFF and was not seen in the 6 hr transferspanels). Staining for BAFF-R at this 6 hr time point indi-
cated that the levels were the same on the transferred used to measure amounts of BAFF that bound to the
transferred cells (Figure 6B). In vitro incubation with sat-cells in the two different recipients. Similar results were
obtained if the donor B cells were autoantigen binding urating amounts of BAFF also led to receptor downregu-
lation (Figure 3C, right panel). By Q-PCR we found simi-cells from Ig/HEL-double transgenic mice, with higher
levels of BAFF being detected on cells transferred to lar levels of BAFF-R mRNA in Ig/HEL- and nontransgenic
B cells (data not shown). TACI mRNA levels were alsodouble transgenic compared to HEL- or nontransgenic
recipients (Figure 3B, lower panels). The similar level of similar between the B cell populations while BCMA ex-
pression was low to undetectable (data not shown).BAFF on Ig/HEL-double transgenic B cells after transfer
to either HEL- or nontransgenic recipients indicates that Taken together, these observations indicate that the
lower levels of BAFF-R on Ig/HEL-double transgenic BBAFF availability is not significantly different whether
the cells are located at the B/T boundary (excluded) or cells are most likely due to the higher levels of BAFF
per B cell in these animals.in the follicle. In the course of this analysis we observed
that Ig/HEL-double transgenic B cells have slightly lower
levels of BAFF-R than nontransgenic B cells (Figure 3C, Constitutively Elevated BAFF Pathway Signaling
in Ig/HEL Double Transgenic Miceleft panel). This was not a consequence of maturation
differences as the majority (65%) of double transgenic To determine whether the amount of BAFF signaling
was greater for B cells in Ig/HEL-double transgenic micespleen B cells were mature (defined by lack of AA4
expression [Allman et al., 2001]) and the difference in compared to B cells in nontransgenic animals, we mea-
sured levels of NFB2, an NFB family member estab-BAFF-R level was also seen with lymph node B cells
Autoreactive B Cell Dependence on BAFF
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Figure 3. B Cells in Ig/HEL-Double Trans-
genic Mice Have More BAFF Bound per Cell
than in Mice with a Diverse B Cell Repertoire
(A) Detection of levels of BAFF bound per B
cell using a rabbit anti-BAFF serum. Freshly
isolated spleen cells from untreated mice
(two left panels), spleen cells incubated in
vitro for 3 hr at 37
C with saturating amounts
of mBAFF-Flag (center right panel), or spleen
cells from an animal treated with 100 g of
BCMA-Ig for 2.5 days (right panel) were
stained using rabbit anti-mouse BAFF serum
or a control rabbit serum as indicated.
(B) Levels of BAFF bound per B cell in Ig/
HEL-, HEL-, and nontransgenic mice. CD45.1
nontransgenic (upper panels) or CD45.1 Ig/
HEL-double-transgenic (lower panel) spleen
cells were transferred into Ig/HEL-double-
transgenic, HEL-transgenic, or nontrans-
genic recipients, as indicated, and 6 hr later
spleens were harvested for FACS analysis.
Left histograms show anti-mouse BAFF
staining and right histograms show anti-
mouse BAFF-R staining on CD45.1CD19
cells in each type of recipient as indicated.
Dotted line, staining with a control rabbit anti-
serum. The distribution of the transferred
cells in recipient spleens (follicular or ex-
cluded from follicles) is indicated. The data
in the upper and lower panels are from experi-
ments performed on different days and there-
fore the staining intensity cannot be directly
compared.
(C) Reduced BAFF-R on B cells in Ig/HEL-
double transgenic mice and cells incubated in vitro with mBAFF-Flag. Left and center panels: CD45.1 nontransgenic spleen cells were
transferred into Ig/HEL-double-transgenic or HEL-transgenic recipients and 12 hr later spleens were harvested for FACS analysis. The left
panel shows anti-mouse BAFF-R staining on endogenous B cells (CD19CD45.1) and the middle panel shows anti-mouse BAFF-R staining
on the transferred B cells (CD19CD45.1). The right panel shows the level of BAFF-R staining on B cells after incubation for 3 hr at 37
C in
the presence or absence of mBAFF-Flag (0.5 g/ml).
lished to function downstream of the BAFF-R (Claudio there is less BAFF available to bind B cells in the compet-
itive environment than in the noncompetitive Ig/HEL-et al., 2002; Kayagaki et al., 2002). Degradation of NFB2
p100 to the active p52 form was measured in follicular double transgenic environment (Figure 3B). To deter-
mine whether BAFF signaling was also reduced, p100B cells sorted from the spleens of Ig/HEL-, non-, or Ig-
transgenic mice (Figure 4A). Autoreactive B cells from and p52 levels were measured in autoantigen binding
cells taken from a competitive environment. Large num-Ig/HEL-double transgenic mice consistently showed
higher p52 levels than detected in naive non- or Ig- bers of CD45.1 Ig/HEL-double transgenic cells were
injected into HEL-transgenic mice and 18 hr later thetransgenic B cells. As BCR stimulation is not thought
to promote p100 processing (Claudio et al., 2002), and recipient spleens were harvested and CD45.1 autoanti-
gen binding B cells isolated by FACS sorting. Consistentother studies have indicated reduced activation of the
classical NFB pathway downstream of the BCR in aner- with the hypothesis that autoantigen binding B cells
receive less BAFF signal in the competitive environment,gic B cells (Healy et al., 1997), it is unlikely that the
increased p52 is due to the BCR stimulation. We also we no longer saw an increase in p52 levels in autoreac-
tive Ig/HEL-double transgenic B cells as compared tomeasured mRNA levels of the BAFF responsive gene,
Pim-2 (Xu et al., 2002), that encodes a kinase recently the endogenous follicular B cells (Figure 4A). Simlarly,
we no longer detected an increase in Pim-2 mRNA inestablished to have prosurvival functions (Fox et al.,
2003; Yan et al., 2003). A consistent 2-fold elevation competing autoantigen binding B cells compared to the
naive B cells isolated from the same animals (Figurein Pim-2 mRNA levels was detected in Ig/HEL-double
transgenic B cells (Figure 4B, left panel). These observa- 4B). p52 protein and Pim-2 mRNA also returned to en-
dogenous B cell levels when Ig/HEL-double transgenictions are consistent with the conclusion that there is
more BAFF available per B cell in Ig/HEL-double trans- B cells were transferred to nontransgenic recipients
(Figures 4A and 4B, rightmost panels), conditions undergenic mice than in animals with a diverse B cell com-
partment. which they experience reduced BCR engagment and
migrate into follicles (Cyster and Goodnow, 1995).
Therefore, the reduction in p52 and Pim2 in HEL-trans-Autoantigen Binding B Cells Competing with Naive
Cells Have Reduced BAFF Signaling genic recipients cannot be explained by increased BCR
engagement or by follicular exclusion of the cells. In-The analysis of BAFF levels and BAFF-R occupancy of
B cells in HEL- and nontransgenic mice showed that stead, these observations favor the conclusion that
Immunity
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Figure 4. Ig/HEL Double Transgenic B Cells
Have Constitutively Elevated BAFF Signaling
but Show Reduced Signaling in the Presence
of Competitor Cells
(A) Western blot analysis of NFB p100 and
p52 levels in autoantigen binding B cells in
the absence and presence of a diverse com-
petitor B cell repertoire. For B cells in the
absence of competition (left panel, lanes 1–3),
B220CD23CD21intermediate follicular B
cells were sorted from the spleens of Ig-,
non-, or Ig/HEL-transgenic mice. For compet-
ing B cells, 2–4 	 107 CD45.1 Ig/HEL-trans-
genic B cells were adoptively transferred into
CD45.2 nontransgenic mice injected with 1
mg of HEL prior to cell transfer (lanes 4 and 5
of left panel); CD45.2 sHEL-transgenic mice
(lanes 6–9 of left panel), or CD45.2 non-
trangenic mice (lanes 1–4 right panel). 18 hr
later, B220 CD21intermediate CD45.1 (Ig/
HEL-double transgenic) or B220CD21in-
termediate CD45.1 (nontransgenic endoge-
nous) B cells were sorted from the recipient
spleens. In the lanes indicated BAFF, the
recipient mice were treated with 50 g of hu-
BAFF-HIS at 0 and 13 hr after transfer. n.s.,
nonspecific band detected with antiserum.
Numbers shown below panels represent the
ratio of p52 to p100 for each sample. In differ-
ent Western blot analyses, the large p100 protein was found to transfer with different efficiencies and therefore the values obtained for the
p52/p100 ratios can only be compared for samples run on the same gel. The left panel represents a single gel (lanes 1–3 were exposed for
longer than lanes 4–9) and the right panel is a separate gel. Data for noncompeting samples are representative of two experiments with sorted
cells and two experiments with autoMACS purified cells.
(B) Pim-2 mRNA levels in autoantigen binding B cells in the absence and presence of competitor B cells. Cells sorted as in (A) were used to
prepare mRNA and the amount of Pim-2 mRNA was measured by quantitative RT-PCR. HPRT message was used as a control for equal mRNA
loading. Panel shows the mean and standard deviation from three Q-PCR runs for the indicated number of independent samples. *p  0.001
for Ig/HEL-tg compared to non-tg or Ig-tg using student’s T test.
when double-transgenic B cells are placed in competi- like the few autoantigen binding cells remaining in un-
treated mice, were excluded from B cell follicles (Figuretion with a full compartment of naive cells, they no longer
receive elevated levels of BAFF and are no longer able 5B). To further explore the relationship between compet-
itive elimination and BAFF dependence, we testedto maintain the exaggerated p52 or Pim-2 levels.
whether increased levels of BAFF could rescue autoanti-
gen binding cells developing within the polyclonal reper-Excess BAFF Can Rescue Autoantigen Binding
toire of mixed bone marrow chimeras. Under these con-B Cells from Competitive Elimination
ditons, about half of the HEL autoantigen binding cellsIf autoreactive B cells require more BAFF for survival
in the spleen are in an immature or transitional stateand do not have enough BAFF available to them when
(Figure 5C). However, as observed in the transfer stud-they are in a compartment with a diverse repertoire of
ies, 3 days of BAFF treatment was able to rescue autoan-competitor B cells, it follows that they may be rescued
tigen binding cells, increasing their numbers to a greaterfrom competitive elimination by excess BAFF. To test
extent than its effect on non-autoantigen binding B cellsthis, Ig/HEL-double transgenic B cells were transferred
(Figures 5C and 5D). This effect was evident in both theinto HEL-transgenic recipients that were treated with
immature AA4 and mature AA4– populations (Figuressaline or BAFF (Figure 5A). While Ig/HEL-double trans-
5C and 5D). Increased numbers of autoantigen bindinggenic B cells were almost completely eliminated from
B cells were also detected in lymph nodes, and theseHEL-transgenic spleens within 2 to 3 days, daily BAFF
cells were predominantly (95%) AA4– mature cells (Fig-treatment was able to partially rescue autoreactive B
ure 5D).cells from competitive elimination (Figure 5A). Western
blot analysis of B cells sorted from BAFF-treated mice
showed that p52 levels were elevated (Figure 4A). During Elevated Bim Levels in Autoantigen Binding B Cells
The increased dependence of HEL-autoantigen bindingthe treatment period, host B cell numbers also in-
creased, although the survival effects of BAFF were B cells on BAFF for survival appeared likely to be due
to increased activity of proapoptotic molecules inducedgreater on the HEL-autoantigen binding B cells (5-fold
increase) than on the endogenous host B cells (less than by chronic autoantigen-mediated BCR stimulation in
these cells. We considered the possibility that the BH3-2-fold increase) (Figure 5A). Analysis of B cell distribu-
tion within the spleen at day 3 after transfer demon- only protein, Bim, may have a role in promoting elimina-
tion of Ig/HEL autoantigen binding B cells, as Bim-defi-strated that BAFF-rescued autoantigen binding B cells,
Autoreactive B Cell Dependence on BAFF
447
Figure 5. Excess BAFF Can Rescue Autoan-
tigen Binding B Cells from Competitive Elimi-
nation
(A) CD45.1 Ig/HEL-double-transgenic spleen
cells were adoptively transferred into CD45.1-
HEL-transgenic mice and recipients were
treated with PBS or hBAFF-HIS (50 g)
twice daily. As a control for maximal rescue
of autoantigen binding cells, Ig/HEL-trans-
genic spleen cells were also transferred into
nontransgenic recipients. Donor T cell num-
bers were monitored as a cell transfer con-
trol. After 2 or 3 days CD45.1CD19 or
CD45.1HEL binding cells and CD45.1CD3
from recipient spleen and lymph nodes were
quantitated. Data shown are the mean (sd)
from 11–16 mice per group, pooled from four
experiments after 2 or 3 days of transfer. Data
are normalized to the nontransgenic recipient
(set at 100%) from each experiment to ac-
count for the different number of B cells trans-
ferred in the separate experiments. *p 
0.001, **p  0.00001 (student’s T test).
(B) Distribution of transferred HEL-autoanti-
gen binding B cells in mice treated for 3 days
with PBS or BAFF. Frozen spleen sections
were stained to detect total B cells (B220,
brown) and transferred HEL binding B cells
(blue). In the experiment shown, BAFF
caused a 3-fold rescue of Ig-transgenic B
cells as determined by FACS quantitation.
(C and D) Rescue of autoreactive B cells in
mixed bone marrow chimeras. HEL-trans-
genic mice reconstituted with a mixture of
CD45.1 Ig-transgenic and CD45.1 non-
transgenic bone marrow (see Experimental
Procedures) were treated with PBS or
hBAFF-HIS (100 g) twice daily for 2.5 days.
In (C), spleen and LN cells were stained to
detect AA4, CD19, CD45.1, and HEL binding.
Left panels show total lymphocyte-size gated
cells with numbers showing percentage of
total cells that were CD19AA4 immature/
transitional cells or CD19AA4 mature cells.
Right panels show the CD19AA4 (upper
panels) or CD19AA4 (lower panels) spleen
cells from PBS- or BAFF-treated mice and
numbers show percentage of total cells
within the indicated gates. In (D) the left and
center panels show the number of HEL bind-
ing CD45.1 CD19 AA4 or AA4 spleen cells or CD45.1 CD19 LN cells and the right panel shows the non-HEL binding CD45.1 CD19
AA4 or AA4 spleen cells and CD45.1 CD19 LN cells as indicated. Data are for three mice per group (mean  sd) and are representative
of two experiments.
cient mice show significantly increased numbers of B increased in competing anergic B cells sorted from HEL
transgenic recipients (Figures 6A and 6B, right panels).cells and B cells from these mice survive for prolonged
periods in vitro (Bouillet et al., 1999). Bim has also been
demonstrated to promote the death of antigen-stimu- Discussion
lated peripheral T cells (Davey et al., 2002; Hildeman
et al., 2002). While our manuscript was in preparation, The above findings demonstrate that mature autoreac-
tive B cells have a greater dependence on BAFF forStrasser and coworkers reported that Bim functions in
the peripheral elimination of autoantigen binding B cells survival than naive B cells. When in a host with a diverse
repertoire of B cells, autoantigen binding cells receive(Enders et al., 2003). Measurements of Bim mRNA and
protein in HEL-autoantigen binding and naive B cells insufficient amounts of BAFF to be protected from BCR-
induced death signals and they are competitively elimi-revealed that B cells from Ig/HEL-double transgenic
mice had increased Bim mRNA (Figure 6A) and protein nated. Bim protein levels are elevated in autoantigen
binding B cells indicating that BAFF must act at least(Figure 6B) compared to B cells from Ig-transgenic or
nontransgenic mice. Bim mRNA and protein were further in part by antagonizing Bim function (Figure 7A). These
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Figure 6. Elevated BIM Levels in HEL Autoantigen Binding B Cells
(A and B) Analysis of Bim mRNA and protein levels in autoantigen binding B cells in the absence and presence of competitor non-autoantigen
binding B cells. Transfers were performed and samples prepared as described in Figure 4. In (A), data shown are the average and standard
deviation from one Q-PCR anlaysis of Bim mRNA relative to HPRT mRNA of the indicated number of sorted B cell samples. *p  0.05 for
comparison of Ig/HEL-tg and non-tg, **p  0.01 for comparison of competiting Ig/HEL-tg and non-tg cells (student’s T test). In (B), Bim
protein was detected by Western blot in the indicated samples using anti-bim polyclonal antibody. Protein levels were determined with anti-
-actin antibodies. The left panel is representative of two experiments with FACS sorted cells.
observations suggest that under conditions where BAFF
levels per B cell are elevated there will be an increased
accumulation of autoantigen binding cells. Reciprocally,
the greater BAFF dependence of autoantigen binding B
cells suggests that treatments that cause partial reduc-
tions in BAFF may selectively deplete the most strongly
autoreactive cells.
A long-running question in the Ig/HEL-transgenic B
cell tolerance model has been to understand why B cells
that are chronically engaged by soluble HEL-autoanti-
gen can survive for more than 1 week in Ig/HEL-double
transgenic mice, where all the B cells are HEL binding,
but survive less than 3 days in mice with a diverse B
cell repertoire (Cook et al., 1997; Cyster and Goodnow,
1995; Cyster et al., 1994; Fulcher and Basten, 1994).
Although differences in antigen-receptor occupancy are
observed under these conditions, with occupancy being
greater in the competitive situation due to the smaller
number of HEL binding B cells, these differences have
not provided a sufficient explanation for the differences
in survival (Cyster, 1997; Phan et al., 2003). In particular,
in Ig/HEL double transgenic mice carrying the highly
expressed albumin promoter-HEL transgene (AL3 line)
rather than the metallothionein promoter-HEL transgene
Figure 7. Proposed Model to Explain Elimination of Autoantigen (ML5 line) (Adelstein et al., 1991), the BCR is fully occu-
Binding B Cells from a Diverse B Cell Repertoire pied yet the cells are not rapidly eliminated (Phan et al.,
(A) The typical B cell in a diverse repertoire receives minimal death 2003; unpublished data). Furthermore, when autoanti-
signals through the BCR. With a constant amount of BAFF, an equi- gen binding cells were transferred in equal numbers to
librium B cell number is achieved where each B cell receives enough
HEL-containing B cell-deficient or wild-type recipients,BAFF to survive many weeks. In a monoclonal Ig/HEL-transgenic
the cells survived in the B cell-deficient recipients whilerepertoire the autoantigen binding B cells receive a stronger death
being rapidly eliminated in the wild-type recipientssignal, involving increased levels of Bim expression, due to chronic
BCR stimulation and these cells are more dependent on BAFF for (Schmidt and Cyster, 1999). Our findings here indicate
survival. Under these conditions the equilibrium is shifted such that that a key difference between the noncompetitive and
there are fewer B cells in the compartment and more BAFF per B competitive situations relates to the amount of BAFF
cell. When autoantigen binding B cells are present in a diverse
available per B cell (Figure 7B). We demonstrate thatrepertoire, the BAFF per B cell ratio is insufficient for the autoantigen
homeostatic BAFF production occurs in a manner thatbinding B cells to be protected from the death signal and they are
is largely independent of the number of B cells in therapidly eliminated.
(B) Suggested relationship between autoantigen-induced BCR sig- host, with spleen and lymph nodes from B cell-deficient
nal strength, BAFF levels, and BAFF dependence for survival. Under mice containing similar amounts of BAFF mRNA as
normal conditions, BAFF levels are fixed, B cell production is in spleen and lymph nodes from wild-type mice. In Ig/HEL-
excess, and only the non- or weakly autoreactive cells that have double transgenic mice, the B cell compartment size
a low or intermediate dependence on BAFF can survive. Under
has been reset to about half to one-third the size of Ig-conditions where BAFF production is elevated or B cell production
single transgenic mice, such that a new equilibrium isis reduced, BAFF levels per B cell are increased allowing strongly
autoreactive B cells that have a higher BAFF dependence to survive. achieved between B cell numbers and the amount of
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BAFF per B cell. Our results indicate that this increased (Avery et al., 2003; O’Connor et al., 2004) and perhaps
also for recirculating bone marrow B cells. Bone marrowlevel of BAFF per B cell, and associated increase in
BAFF-R signaling, is critical for the ability of the autoanti- expression is likely to contribute to systemic levels of
BAFF and thereby influence the size of the mature Bgen-engaged cells to survive for more than a few days.
Reciprocally, the greater dependence of HEL-autoanti- cell compartment.
The mechanism by which BCR signaling promotes Bgen binding B cells on BAFF causes them to be poor
competitors relative to non-autoantigen binding B cells. cell death is not fully defined, but many studies have
indicated that Bcl-2 overexpression can provide someWhen in a diverse B cell compartment they cannot main-
tain the higher levels of BAFF-R signaling required to protection from BCR-induced apoptosis. The proapo-
ptotic molecule, Bim, has been established to play aovercome the BCR-induced death signal and they are
deleted (Figure 7). role in elimination of antigen- and autoantigen- binding
T cells (Bouillet et al., 2002; Davey et al., 2002; HildemanIn earlier studies, a correlation was observed between
exclusion of autoantigen binding B cells from lymphoid et al., 2002) and to function in promoting B cell homeo-
stasis (Bouillet et al., 1999). In work that appeared whilefollicles and rapid elimination of the cells (Cyster et al.,
1994). To examine whether this might reflect BAFF being our study was in preparation, Enders et al. demonstrated
that Bim is involved in elimination of in vitro anti-IgM-present at higher levels in follicles than in the T zone or
other sites, we attempted to determine the distribution stimulated cells and that it is required for in vivo elimina-
tion of HEL-autoantigen binding B cells (Enders et al.,of BAFF within secondary lymphoid tissues. BAFF
mRNA was detected at highest levels in lymphoid tissue 2003). This study also demonstrated that anti-IgM-stim-
ulated cells exhibited a small increase in Bim proteinstromal preparations and was not significantly dimin-
ished in CSF1-deficient mice that lack many macro- levels (Enders et al., 2003). Our finding that Bim mRNA
and protein levels are elevated in freshly isolated HEL-phages, consistent with a recent report demonstrating
that BAFF is made predominantly by radiation-resistant autoantigen binding B cells is in agreement with these
observations. Based on these combined data, we con-cells (Gorelik et al., 2003). We also examined expression
levels in the spleen of LT/ or TNF-deficient mice as sider that the most straightforward explanation for how
BAFF protects HEL-autoantigen binding B cells fromthese animals are deficient in lymphoid stromal cells,
particularly FDCs (Fu and Chaplin, 1999). The spleen elimination is by antagonizing Bim function. In vitro stud-
ies have shown that prosurvival Bcl-2 family memberstissues from these animals maintained levels of BAFF
mRNA that were not significantly different from wild- Bcl-xL, A1, and possibly Bcl-2 are upregulated by BAFF
(Claudio et al., 2002; Hatada et al., 2003), although it hastype controls. Thus, although the quantitative PCR ap-
proach does not exclude the possibility of a reduction been less clear whether these molecules are regulated in
vivo by BAFF. During our study we measured mRNAof up to 30%–40% in BAFF expression, it would appear
that mature FDC are not a major source of BAFF. At- levels of Bcl-2, Bcl-xL, A1, and Mcl-1 in cells exposed
to increased or decreased amounts of BAFF. Althoughtempts to more precisely determine the location of
BAFF-producing cells using rabbit antibodies raised we observed upregulation of Bcl-2, Bcl-xL, and A1
mRNA by quantitative PCR analysis after 6 hr in vitroagainst both the extracellular and cytoplasmic domains
of BAFF have so far been unsuccessful (not shown). The culture with BAFF (not shown), increased expression of
these genes was not maintained upon longer (24 hr)finding that levels of BAFF bound to transferred Ig/HEL-
double transgenic B cells was equivalent whether the incubation. Moreover, in in vivo studies where mice were
treated with BAFF to augment signaling or with BCMA-cells were excluded from follicles (in HEL-transgenic
recipients) or localized within follicles (in nontransgenic Ig to inhibit BAFF signaling, we did not observe any
reproducible effects on levels of Bcl-2, Bcl-xL, A1, orrecipients) suggests that follicular access is not a major
factor determining the extent of access to BAFF. Consis- Mcl-1 mRNAs in purified B cells (not shown). However,
we were able to detect increases in the levels of mRNAtent with the notion that the B cell competition for BAFF
is not dependent on compartmental segregation, we for Pim-2, a ser/thr kinase that has recently been shown
to function as a prosurvival molecule downstream ofhave recently found that CCR7/ Ig/HEL-double trans-
genic B cells are not excluded from the B cell follicle, hematopoetic growth factors (Fox et al., 2003; Yan et
al., 2003), and to interact with the BH3-only molecule,yet still undergo rapid cell death when in a diverse B
cell repertoire (Ekland et al., 2004). Bad (Yan et al., 2003). Pim-2 was also identified as an
NFB regulated gene but it is not yet known if it isWhile BAFF expression in the spleen was not strongly
dependent on LT or , the requirement of this cytokine induced by p52 complexes (Li et al., 2001). A full charac-
terization of Pim-2-deficient mice has not been reported,for lymph node and Peyer’s patch development means
that a fraction of the BAFF produced in the body is although it has been stated that these animals are phe-
notypically normal (Allen and Berns, 1996). It will beabsent in mice lacking LT/. We speculate that this
reduces total BAFF levels in the body and therefore that important in future studies to determine whether autoan-
tigen binding B cells are more readily eliminated inthere is a corresponding reduction in total body B cells.
In addition to expression in secondary lymphoid organs, these animals.
While our studies indicate that differential depen-we found it notable that BAFF was expressed at high
levels within the bone marrow. Expression has also been dence on BAFF contributes to the competitive elimina-
tion of autoantigen binding B cells, they do not excludedetected in human bone marrow (Moore et al., 1999).
However, BAFF is not thought to be required for B cell the possiblity that B cells compete for additional prosur-
vival activities. In this regard, we previously found thatdevelopment in the bone marrow (Schiemann et al.,
2001). Instead bone marrow BAFF most likely plays an autoantigen binding B cell survival was augmented in
an antigen nonspecific manner by the presence of T cellsimportant role in the survival of long-lived plasma cells
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(Schmidt and Cyster, 1999). Survival of Btk-deficient B may have therapeutic benefit in patients prone to devel-
oping autoantibody-mediated diseases.cells is also augmented by T cells (Karagogeos et al.,
1986). As naive T cells are not a source of BAFF and
Experimental Procedureswe have not observed reduced BAFF levels in spleens
from T cell-deficient mice (not shown), this effect most
Reagents
likely involves another B cell trophic activity. There is Human BCMA-Ig and human IgG control were produced as de-
also the possibility that proapoptotic signaling increases scribed (Thompson et al., 2000). Hamster anti-mBAFF-R (B9C11)
when autoantigen binding B cells are competing with was prepared as described (Gorelik et al., 2004). Human BCMA-Ig
neutralizes both mBAFF and mAPRIL (Schneider et al., 2001). Humanother B cells. The increased Bim levels in competing
soluble HIS-BAFF (aa 134-285) used for in vivo BAFF treatmentscompared to noncompeting autoantigen binding B cells
was produced as described (Liu et al., 2002). In one experiment with(Figure 5) is consistent with this possibility. We exam-
mixed bone marrow chimeras, human soluble myc-BAFF (Karpusas
ined whether the rise in Bim levels might be secondary et al., 2002) was used with similar results. To generate antibodies
to the reduced BAFF availability but have so far not against mouse BAFF, the extracellular region (aa 127-310) with an
observed an effect of increasing or decreasing BAFF in NH2-terminal HIS-tag was expressed in the pET expression system
in BL21 bacteria. The band corresponding to mouse HIS-BAFF wasvivo on B cell Bim mRNA levels (R.L., Y. X., and J.G.C.,
cut from an SDS-PAGE gel and used as an immunogen to generateunpublished data). Therefore, in addition to the competi-
rabbit polyclonal anti-mouse BAFF serum. To generate antibodiestion for BAFF demonstrated here, competitive elimina-
against the mouse BAFF cytoplasmic domain, amino acids 1-45
tion of B cells may involve elevated proapoptotic signal- were expressed as a GST fusion protein and the affinity purified
ing and possibly competition for other trophic factors. protein was used as an immunogen in rabbits. The anti-cytoplasmic
Several reports have demonstrated a relationship be- domain antibody was used as a staining control in some flow cyto-
metric experiments. Rabbit polyclonal anti-p52 (raised against aatween BAFF levels and autoantibody-mediated disease.
1-399) was a kind gift of U. Siebenlist (Laboratory of Immunoregula-Transgenic mice overexpressing BAFF develop rheuma-
tion, NIAID). Mouse soluble BAFF-Flag was produced by transientlytoid factor, anti-DNA, and anti-nuclear antibodies (Gross
transfecting 293T cells with a pEF vector containing mouse BAFF
et al., 2000; Khare et al., 2000; Mackay et al., 1999), and amino acids 127-310 with an NH2-terminal prolactin signal sequence
some animals show features of Sjo¨gren’s syndrome (SS) and FLAG-tag (vector as described in Gunn et al. [1998]) or pur-
(Groom et al., 2002). Furthermore, serum BAFF levels chased from Alexis Biochemicals.
and B cell p52 levels are elevated in lupus prone NZB/W
AnimalsF1 mice (Gross et al., 2000; Kayagaki et al., 2002) and
Ig/HEL double transgenic mice were generated by crossing HEL-BAFF levels are high in a fraction of human lupus, RA,
specific MD4 Ig transgenic mice (Goodnow et al., 1988) to ML5 sHELand SS patients (Groom et al., 2002; Zhang et al., 2001).
Tg mice (Adelstein et al., 1991) or by making radiation chimeras as
Our findings indicate that elevated BAFF levels may described (Cyster and Goodnow, 1995) using MD4 Ig transgenic
predispose to autoimmunity by increasing the threshold bone marrow to repopulate lethally irradiated (1100 Rads) ML5 sHEL
transgenic mice. Rag1/, MT mice were purchased from Jacksonamount of chronic BCR signaling that is required to
Laboratories. Tissues from TNF/, LT, LT, op/, and op/op micecause B cell deletion in the periphery (Figure 7B). There-
were prepared as previously described (Ngo et al., 1999). Mixedfore, individuals with high BAFF levels might have a
bone marrow chimeras were produced by reconstituting ML5 homo-higher burden of autoantigen binding B cells in the pe-
zygous transgenic mice with 80% CD45.1 Ig-transgenic bone mar-
riphery. The recent demonstration that many of the B row and 20% CD45.2 nontransgenic bone marrow as previously
cells that emerge into the periphery in humans are auto- (Cyster et al., 1994). Analysis of the immature bone marrow B cell
compartment of reconstituted mixed chimeras revealed that HELreactive and that a fraction of these specificities are
binding B cells represented about 20%–30% of the cells, whereasnormally purged prior to full maturation highlights how
only 2%–5% of peripheral B cells were HEL binding, as in previousshifts in BAFF levels might readily affect the fraction of
studies (Cyster et al., 1994).the mature B cell repertoire that is autoreactive (Warde-
mann et al., 2003). Moreover, the association between Adoptive Transfer
B cell deficiency and the development of systemic auto- Adoptive transfers were intravenous, and unless otherwise noted,
immune diseases such as autoimmune hemolytic ane- intraperitoneal treatments with BAFF or BCMA-Ig were begun at
the time of cell transfer. All donors and recipients were sex matched.mia (August and Hathaway, 1989) might be a conse-
In most cases, T cells in the donor spleen or LN preparations werequence of the higher BAFF levels per B cell in
used to confirm uniformity of cell transfer numbers in each animal.immunodeficient states. We consider it less likely that
To study competition, Ig/HEL double transgenic spleen cells were
BAFF overproduction rescues cells from deletion in the injected intravenously into HEL transgenic recipients. Spleen cells
bone marrow as immature bone marrow B cells express were injected such that each recipient received 5–10 	 106 Ig/HEL
little if any BAFF-R (Gorelik et al., 2004; Hsu et al., 2002; double transgenic B cells.
and unpublished data) and addition of BAFF to bone
Flow Cytometrymarrow B cells in an in vitro B cell tolerance model failed
Single cell suspensions from spleen, mesenteric, and brachial lymphto rescue the BCR engaged cells (Rolink et al., 2002).
nodes, or blood (RBC lysed) were incubated with various antibodies
Conversely, it seems likely that the absence of BAFF-R for four-color flow cytometry on a Becton Dickinson FACS Caliber.
on immature cells helps ensure that they are deleted Monoclonal antibodies to CD19, CD45.1, CD3, CD4, CD8, CD19,
when persistently engaged by multivalent self-antigen. B220, IgDa, IgMa, CD21, and CD23 were from BD Pharmingen (San
Diego, CA), as was polyclonal goat anti-Rabbit biotin. HyHEL9-tri-Finally, the greater dependence of chronically engaged
color and HyHEL9-PECy5.5 were from custom conjugations per-peripheral B cells on BAFF suggests that treatments
formed by Caltag laboratories. AA4-PE was a gift of D. Allman. Anti-that cause only partial blocking of BAFF, and thus have
Flag-biotin (M2) was from Sigma and was preadsorbed with 4%
minimal effects on naive B cell numbers, may be effec- normal rat and mouse serum to prevent background staining. Strep-
tive in eliminating autoreactive B cells without disrupting tavidin-APC was from Molecular Probes (Eugene, OR). Follicular
B220 CD21intermediate CD23 B cells were isolated on a MoFloB cell immunity. Thus, even partial BAFF antagonism
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